Ameriprise’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $191M | Sell |
1,109,387
-274,996
| -20% | -$51M | 0.04% | 377 |
|
|
2025
Q4 | $276M | Buy |
1,384,383
+770,779
| +126% | +$140M | 0.06% | 297 |
|
|
2025
Q3 | $96M | Buy |
613,604
+575,039
| +1,491% | +$91.3M | 0.02% | 581 |
|
|
2025
Q2 | $5.85M | Sell |
38,565
-506,260
| -93% | -$67.5M | ﹤0.01% | 2243 |
|
|
2025
Q1 | $82M | Buy |
544,825
+321,789
| +144% | +$54M | 0.02% | 613 |
|
|
2024
Q4 | $41.2M | Buy |
223,036
+9,847
| +5% | +$1.9M | 0.01% | 935 |
|
|
2024
Q3 | $42M | Sell |
213,189
-148,660
| -41% | -$30.9M | 0.01% | 924 |
|
|
2024
Q2 | $74.8M | Buy |
361,849
+79,113
| +28% | +$17.9M | 0.02% | 633 |
|
|
2024
Q1 | $76.6M | Buy |
282,736
+259,151
| +1,099% | +$61.9M | 0.02% | 638 |
|
|
2023
Q4 | $5.58M | Sell |
23,585
-1,417
| -6% | -$279K | ﹤0.01% | 2262 |
|
|
2023
Q3 | $4.9M | Buy |
25,002
+1,490
| +6% | +$306K | ﹤0.01% | 2307 |
|
|
2023
Q2 | $4.94M | Buy |
23,512
+1,291
| +6% | +$257K | ﹤0.01% | 2353 |
|
|
2023
Q1 | $4.48M | Sell |
22,221
-296,276
| -93% | -$67.1M | ﹤0.01% | 2398 |
|
|
2022
Q4 | $69.4M | Buy |
318,497
+299,953
| +1,618% | +$65.5M | 0.02% | 606 |
|
|
2022
Q3 | $3.65M | Sell |
18,544
-1,103
| -6% | -$238K | ﹤0.01% | 2451 |
|
|
2022
Q2 | $4.2M | Sell |
19,647
-7,019
| -26% | -$1.72M | ﹤0.01% | 2407 |
|
|
2022
Q1 | $7.45M | Sell |
26,666
-802
| -3% | -$247K | ﹤0.01% | 2150 |
|
|
2021
Q4 | $10.3M | Sell |
27,468
-231,940
| -89% | -$90.1M | ﹤0.01% | 1967 |
|
|
2021
Q3 | $107M | Sell |
259,408
-581,623
| -69% | -$242M | 0.03% | 503 |
|
|
2021
Q2 | $311M | Sell |
841,031
-67,474
| -7% | -$22.5M | 0.1% | 219 |
|
|
2021
Q1 | $263M | Sell |
908,505
-241,402
| -21% | -$67.1M | 0.09% | 233 |
|
|
2020
Q4 | $287M | Buy |
1,149,907
+388,345
| +51% | +$92.5M | 0.1% | 208 |
|
|
2020
Q3 | $172M | Buy |
761,562
+448,012
| +143% | +$93M | 0.07% | 279 |
|
|
2020
Q2 | $54.6M | Buy |
313,550
+2,390
| +0.8% | +$381K | 0.02% | 591 |
|
|
2020
Q1 | $39.2M | Sell |
311,160
-136,109
| -30% | -$20.4M | 0.02% | 638 |
|
|
2019
Q4 | $68.3M | Sell |
447,269
-231,850
| -34% | -$32.1M | 0.03% | 563 |
|
|
2019
Q3 | $89.9M | Buy |
679,119
+111,365
| +20% | +$14.9M | 0.04% | 441 |
|
|
2019
Q2 | $80.6M | Buy |
567,754
+142,415
| +33% | +$19.3M | 0.04% | 489 |
|
|
2019
Q1 | $61.8M | Buy |
425,339
+70,276
| +20% | +$9.23M | 0.03% | 566 |
|
|
2018
Q4 | $40.2M | Sell |
355,063
-21,240
| -6% | -$2.66M | 0.02% | 704 |
|
|
2018
Q3 | $50.5M | Buy |
376,303
+118,496
| +46% | +$14.6M | 0.02% | 748 |
|
|
2018
Q2 | $28.9M | Buy |
257,807
+69,463
| +37% | +$7.51M | 0.01% | 940 |
|
|
2018
Q1 | $20.1M | Buy |
188,344
+7,754
| +4% | +$836K | 0.01% | 1115 |
|
|
2017
Q4 | $19.8M | Sell |
180,590
-5,257
| -3% | -$572K | 0.01% | 1072 |
|
|
2017
Q3 | $20.1M | Buy |
185,847
+12,903
| +7% | +$1.33M | 0.01% | 1033 |
|
|
2017
Q2 | $17.5M | Buy |
172,944
+2,246
| +1% | +$207K | 0.01% | 1132 |
|
|
2017
Q1 | $15.4M | Buy |
170,698
+5,088
| +3% | +$432K | 0.01% | 1203 |
|
|
2016
Q4 | $12.6M | Buy |
165,610
+33,585
| +25% | +$2.55M | 0.01% | 1328 |
|
|
2016
Q3 | $11M | Buy |
132,025
+2,062
| +2% | +$173K | 0.01% | 1368 |
|
|
2016
Q2 | $10.7M | Buy |
129,963
+5,243
| +4% | +$432K | 0.01% | 1328 |
|
|
2016
Q1 | $9.47M | Sell |
124,720
-11,933
| -9% | -$883K | 0.01% | 1454 |
|
|
2015
Q4 | $11M | Buy |
136,653
+1,151
| +0.8% | +$83K | 0.01% | 1377 |
|
|
2015
Q3 | $8.61M | Buy |
135,502
+3,231
| +2% | +$232K | 0.01% | 1582 |
|
|
2015
Q2 | $9.3M | Sell |
132,271
-125,550
| -49% | -$9.29M | 0.01% | 1660 |
|
|
2015
Q1 | $20.4M | Buy |
257,821
+23,894
| +10% | +$1.76M | 0.01% | 993 |
|
|
2014
Q4 | $14.9M | Sell |
233,927
-53,801
| -19% | -$3.37M | 0.01% | 1162 |
|
|
2014
Q3 | $17.2M | Sell |
287,728
-36,960
| -11% | -$2.11M | 0.01% | 1062 |
|
|
2014
Q2 | $17.4M | Sell |
324,688
-49,035
| -13% | -$2.69M | 0.01% | 1121 |
|
|
2014
Q1 | $22.5M | Buy |
373,723
+66,878
| +22% | +$3.9M | 0.01% | 925 |
|
|
2013
Q4 | $16.3M | Buy |
306,845
+4,607
| +2% | +$231K | 0.01% | 1152 |
|
|
2013
Q3 | $14M | Buy |
302,238
+10,972
| +4% | +$503K | 0.01% | 1237 |
|
|
2013
Q2 | $11.9M | Buy |
+291,266
| New | +$12.5M | 0.01% | 1311 |
|
Other funds holding CRL
VCM
VPM
Ameriprise's CRL Position: Q1 2026 in Review
Ameriprise reduced its Charles River Laboratories (CRL) stake by 20% in Q1 2026, selling an estimated $51M and leaving 1,109,387 shares worth $191M. The position accounts for 0.04% of the portfolio, ranked #377.
Ameriprise first reported a position in CRL in Q2 2013 and has held it in 52 quarters since. The position peaked at $311M in Q2 2021. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Ameriprise held 1,109,387 shares of Charles River Laboratories worth $191M as of Q1 2026.
- Ameriprise sold 274,996 Charles River Laboratories shares in Q1 2026, an estimated $51M.
- Charles River Laboratories made up 0.04% of Ameriprise's portfolio in Q1 2026, its #377 holding.
- Ameriprise first reported a position in Charles River Laboratories in Q2 2013 and has held it in 52 quarters since.
- Ameriprise's Charles River Laboratories position peaked at $311M in Q2 2021.
- 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.